Organogenesis (NASDAQ:ORGO) Given New $6.00 Price Target at Morgan Stanley

Organogenesis (NASDAQ:ORGO - Free Report) had its target price raised by Morgan Stanley from $4.00 to $6.00 in a research report sent to investors on Wednesday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

Organogenesis Stock Performance

Shares of Organogenesis stock traded down $0.48 during trading on Wednesday, hitting $5.16. 1,343,552 shares of the company's stock were exchanged, compared to its average volume of 1,069,830. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The business has a 50-day simple moving average of $3.65 and a 200-day simple moving average of $3.35. Organogenesis has a 52-week low of $2.17 and a 52-week high of $6.71. The stock has a market capitalization of $654.43 million, a price-to-earnings ratio of -86.00 and a beta of 1.66.

Insider Buying and Selling

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now owns 166,879 shares in the company, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Gary S. Gillheeney sold 55,615 shares of the firm's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $3.36, for a total transaction of $186,866.40. Following the sale, the chief executive officer now owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. This represents a 1.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 284,700 shares of company stock valued at $1,051,472 over the last 90 days. Insiders own 36.90% of the company's stock.

Remove Ads

Institutional Trading of Organogenesis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ORGO. Captrust Financial Advisors acquired a new stake in shares of Organogenesis in the third quarter valued at about $36,000. Virtu Financial LLC acquired a new stake in shares of Organogenesis in the fourth quarter valued at about $38,000. Intech Investment Management LLC acquired a new stake in shares of Organogenesis in the third quarter valued at about $43,000. Palumbo Wealth Management LLC acquired a new stake in shares of Organogenesis in the fourth quarter valued at about $65,000. Finally, ProShare Advisors LLC grew its position in shares of Organogenesis by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock valued at $65,000 after purchasing an additional 6,689 shares during the period. Institutional investors and hedge funds own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.